KT Corporation and Hanmi Pharmaceutical have co-invested in Digital Pharm. The companies announced on June 19, 2022 that KT and Hanmi completed their investments in Digital Pharm and held a launch ceremony. This business alliance is the first case in which Korea's leading information and communication technology (ICT) companies, pharmaceutical companies, and medical institutions have partnered to exploit their respective capabilities.

Digital Pharm, a subsidiary of Catholic University of Korea Technology Holding Company, was founded in November 2021 by Professor Kim Dai-jin of Catholic University's Seoul St. Mary's Hospital. In the future, KT plans to develop a digital treatment platform, establish business strategies for the new company, and build a pipeline of digital treatment devices and electroceuticals.

Hanmi will establish digital therapeutics B2H (business to hospital) and sales and marketing strategies to activate the nascent digital therapeutics prescription market. KT and Hanmi plan to drive additional value through strategic licenses. Digital Pharm's ongoing business will be to discover new DTx pipelines in various disease areas and support the clinical research infrastructure essential for commercial development.

It is scheduled to start a confirmatory clinical trial in the second half of the year for an addiction-related digital treatment e-medication targeting alcohol and nicotine, which is currently under development. In addition, Digital Pharm will focus on developing digital therapies for various diseases, such as hearing loss and dysphagia, and the platforms to allow them to be used remotely. KT is also conducting an exploratory clinical trial for a digital therapeutic to treat chronic heart failure, and expects to see results within the year.

In addition, it is planning to target the domestic market by securing a commercial license for NeuroSigma's FDA-cleared digital therapeutic device targeting attention deficit hyperactivity disorder (ADHD) and potentially other disorders such as epilepsy.